Badr El Khouzai

Woke up to see the @QuadShotNews mentioning new @myESMO guidelines for prostate cancer. Congrats to @PBlanchardMD @stefanofanti4 @Silke_Gillessen @Prof_Nick_James @piet_ost @PCaParker @Tilki_De @alison_tree @ZilliThomas et al on this Oscar of Oncology award from USA 🇺🇸 😀👏

Extremely excited to share our latest article published @TheLancetOncol a few hours ago: authors.elsevier.com/a/1mYT65EIIgTS…. The WOLVERINE individual patient meta-analysis was an international collaboration and part of X-MET collaboration. Goal was to evaluate MDT in oligomet prostate ca.

🚨 New @TheLancet Seminar: #ProstateCancer🚨 Key takeaways ⬇️ 🧬 Biology & heterogeneity matter Prostate cancer isn’t one disease—molecular subtypes (eg, BRCA2, PTEN, AR alterations) increasingly guide therapy 🔍 Diagnosis has evolved MRI-first pathways + PSMA PET outperform conventional imaging, but raise questions about stage migration ⏸️ Active surveillance is standard Preferred for low-risk disease and select intermediate-risk pts—reduces overtreatment with excellent long-term outcomes 🏥 Local therapy ≈ equivalent cancer control Surgery, EBRT, brachytherapy all effective—decision hinges on toxicity profiles & patient preferences 🔥 High-risk disease = multimodal RT + long-term ADT ± ARPIs now core; surgery often part of a combined strategy 🌍 Metastatic landscape transformed ADT + ARPI (± docetaxel) improves OS; triplet therapy for fit, high-volume pts 🎯 Targeted & radioligand therapies PARP inhibitors (BRCA-driven benefit) and Lu-177–PSMA are reshaping mCRPC care 🤝 Shared decision-making is central Toxicity, quality of life, and sequencing remain key unanswered questions Essential read for anyone treating prostate cancer 👇 @PCF_Science @PCFnews @urotoday @UrologyTimes @Ecastromarcos @alison_tree 🔗shorturl.at/xZti6

@h_mehanna @H_N_C_I_G presents results of CompARE trial at #ESMO26 on the use of induction and adjuvant durvalumab to concurrent CRT for oropharyngeal cancer. No benefit overall in DFS or OS. possible benefit in high risk patients. No added toxicity.

STOPCAP at #ESMO26 Benefit of #radiotherapy in de novo M1 #prostatecancer on OS & PFS. Restricted to <5 bone or low volume mets on conventional imaging. No interaction with other patient/tumor characteristics.

🧬 Cribriform architecture changes the story in localized prostate cancer. 🔥 ProtecT 15-year biopsy re-review shows who really needs treatment vs surveillance. 🎯 n = 712 with available slides (13 % cribriform+) 💊 Arms: ▫️ Active monitoring ▫️ Radical prostatectomy ▫️ Radiotherapy + neoadjuvant ADT 📊 Key Results • Cribriform + → ↑ metastasis risk (HR 3.61, 95 % CI 1.60-8.11) • RT + ADT → lowest metastasis (HR 0.35 vs active monitoring) • Surgery → HR 0.52 vs active monitoring (NS) • 15-yr metastasis (cribriform +): AM 25 % | Surg 26 % | RT + ADT 8 % • Cribriform –: 7 % | 4 % | 3 % ✅ Takeaway: Cribriform + = treat aggressively (RT + ADT best long-term control) Cribriform – = active surveillance still safe for most patients. 📖 Sushentsev et al. JAMA Oncology 2025. 🔗 doi.org/10.1001/jamaon… #OncoTwitter #MedTwitter #ProstateCancer #UroOnc @OncoAlert @myesmo @esmo_open @ASCO @JAMAOnc

De escalated therapy is safe for stage IIA-IIB seminoma! ✅No recurrence since initial presentation in 2021. ✅No severe toxicity. ✅Secondary malignancies only outside of radiotherapy fields. Long term outcomes of SAKK 01/10 by @Alex_Papachris at #ESMO2

The RAMPP trial has landed ‼️ Congratulations to the authors for this great work!! It compared best systemic therapy + RP (with extended LND) to BST alone for patients with de-novo synchronous oligometastatic PCa, defined as =< 5 bone mets. BST consisted of lifelong ADT. It closed early due to STAMPEDE results. Cancer-Specific mortality was the primary enpoint. Clinical progression and OS were secondary endpoints. An X-torial 1/n @euplatinum @urotoday @dr_coops @chapinmd @pcaparker @soum_roy_radonc @drspratticus @drandrewloblaw @tylersbrt @seanmmcbride @sbrtsean @alison_tree @vedangmurthy @piet_ost @paulsargos @jryckman3 @5_utr @protonstorey @docpriyamvada @_shankarsiva @alexsherrymd @albertobossial @xristodouleas @amarukishan @zklaassen_md @themednet #OncoTwitter #ProstateCancer #RadOnc #UroOnc @oncoalert #s0075" target="_blank" rel="nofollow noopener">sciencedirect.com/science/articl…

STORM-PEACE V trial reported by @ZilliThomas #ESTRO25 Pelvic ENI superior to MDT for pelvic relapses after local Tx for #prostate cancer (6mo ADT each) Improves Biochemical PFS Locoregional PFS MFS ADT free survival Tox NS ENI clear SOC Online @TheLancetOncol Cc @piet_ost

SBRT (6*6Gy) is a new treatment option for small oral cavity cancers (T1-2) at risk of local recurrence after resection (R1, PNI..): Julian Biau reports the STEREOPOSTOP GORTEC 2017-03. Convenient Fast Similar outcomes than post op brachy Mostly VMAT homogeneous plans #ESTRO25

Bladder preservation is a philosophy—not just a protocol. A 15-year journey in bladder preservation at @RadOncTMC . @TataMemorial @ACTREC_TMC From pioneering Adaptive Radiotherapy (ART) to safely transitioning to hypofractionation, our story, in @IJROBP #RadOnc #bladdercancer

Kinetics of PSMA PET signal after radiotherapy in 217 prostate cancer lesions: It takes multiple months for the uptake to decrease (> 6 months). Beware of "pseudo-progression" on PSMA PET performed shortly after RT. @RO_GreenJournal @masatoshihotta @UCLA sciencedirect.com/science/articl…

Thanks to @DavidSherMD for the invitation to contribute to this special issue in Seminars in Radiation Oncology on #precisionradiotherapy Personalising #NasopharyngealCancer #NPC : Systemic Therapy and Radiotherapy sciencedirect.com/science/articl…

Timing matters? ⏰ Morning ☢️⬆️ survival in NPC without added toxicity. Should we rethink RT scheduling? 🤔@OncoAlert 🎯Objective: •Investigate the impact of ☢️ timing (morning, afternoon, night) on OS and toxicity in NPC 🔬Methods: •Retrospective analysis of 1,040 NPC 👥 treated w/ IMRT •👥 grouped by treatment ⌚: Morning (6:00-11:59), Afternoon (12:00-17:59), Night (18:00-24:00) •PSM and Cox used to ⚖️ confounders 📊Results: •Morning RT ⬆️ OS •HR: Afternoon (5.88, P=.004), Night (4.81, P=.018)😱 •N🚫 difference in acute toxicity between groups 🗣Conclusion: Morning ☢️ ⬆️survival for NPC. Prospective studies are needed to confirm findings❗️

PEACE-1 RT is now published online at @TheLancet Some differences with STAMPEDE Key messages: RT to prostate in M1 #prostatecancer 1. improves rPFS but not OS in low volume 2. improves CRPC-FS & reduces serious GU SAE irrespective of volume Full text: thelancet.com/journals/lance…

Excited to see HN004 out in publication! In Star Wars terms, if HN005 is Seventy Gray Strikes Back, then HN004 is The Rise of Cetuximab thelancet.com/journals/lanon…

Delighted to share the results of #PACE B trial, published in @NEJM today 5 fraction SBRT is non inferior to CRT! nejm.org/media/doi/full… @alison_tree @ICR_CTSU @EmmaHall71 @royalmarsdenNHS @DrAndrewLoblaw @cpeedell @DrTolan @ProfJOSullivan @DrSuneil_PCa

Short-course versus no ADT in RADICALS-HD ⁦@PCaParker⁩ pubmed.ncbi.nlm.nih.gov/38763154/

1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC. nejm.org/doi/full/10.10…